As this season's football teams celebrated their respective division championships with champagne, with corks flying around the room painting each others' faces with the pressurized spray, I was motivated to warn my readers about avoiding a potentially devastating eye injury.
Just three months ag
Poor Genentech. The company is making the news frequently these days. And it?s not about new drug discoveries or other scientific breakthroughs that is earning the company such press, but rumors of the compan
Welcome to the VisiVite Blog, featuring subjects about eye health and alternative treatments for macular degeneration and dry eye syndrome, in particular.? My intention for the blog is to discuss the the latest eye health news, eye care research, and alternative eye treatment solutions. I also hope
It seems highly unlikely that one company would produce two drugs, at different prices, that treat the same ailment, and be in the middle of a medical industry dispute, but that's exactly the case of Genentech Inc.
Lucentis, a federally approved drug for the most severe form of macular degenerati